Related Experiment Video
Updated: Dec 13, 2025
10:41
Wild-type Blocking PCR Combined with Direct Sequencing as a Highly Sensitive Method for Detection of Low-Frequency Somatic Mutations
Published on: March 29, 2017
12.2K
Single-Nucleotide Polymorphism Array Technique Generating Valuable Risk-Stratification Information for Patients With
Xia Xiao1, Xiaoyuan He2, Qing Li1
1Department of Hematology, Tianjin First Central Hospital, Tianjin, China.
Frontiers in Oncology
|August 1, 2020
Summary
Single-nucleotide polymorphism array (SNP-A) detects chromosomal abnormalities missed by conventional methods, improving diagnosis and prognosis for myelodysplastic syndromes (MDS) and idiopathic cytopenia of undetermined significance (ICUS). SNP-A identifies patients with poor prognosis and aids in reclassifying ICUS to MDS.
Area of Science:
- Hematology
- Genetics
- Oncology
Background:
- Chromosomal abnormalities are critical for diagnosing and predicting outcomes in myelodysplastic syndromes (MDS).
- Single-nucleotide polymorphism array (SNP-A) offers higher resolution than metaphase cytogenetics (MC) for detecting genetic aberrations.
Purpose of the Study:
- To evaluate the diagnostic and prognostic significance of SNP-A in detecting chromosomal abnormalities in MDS and related disorders.
- To assess SNP-A's utility in identifying submicroscopic aberrations and predicting disease progression in MDS and idiopathic cytopenia of undetermined significance (ICUS).
Main Methods:
- A cohort of 376 individuals, including 350 patients with MDS, myeloproliferative neoplasm (MPN), acute myeloid leukemia (AML), and ICUS, and 26 healthy controls, were analyzed.
- SNP-A was employed to detect chromosomal abnormalities, comparing its efficacy with conventional MC analysis.
- Prognostic value was assessed by correlating SNP-A findings with overall survival (OS) and progression-free survival (PFS).
Main Results:
- SNP-A detected submicroscopic/cryptic aberrations missed by MC in 32.8% of MDS, 30.8% of MPN, and 30% of AML patients.
- Abnormalities detected by SNP-A significantly correlated with poorer OS (P=0.001) and PFS (P=0.008) in MDS patients, especially in the low-risk group.
- Multiple SNP-A abnormalities (≥3) independently predicted poor prognosis in MDS (HR=2.40, P=0.002).
- SNP-A identified 17 ICUS patients who later developed MDS, highlighting its role in assessing ICUS evolution.
Conclusions:
- SNP-A enhances the detection of chromosomal abnormalities in MDS and related myeloid neoplasms.
- SNP-A provides valuable prognostic information for MDS patients, particularly those at low risk.
- SNP-A aids in risk stratification and monitoring disease progression in ICUS, potentially leading to earlier MDS diagnosis.
